Nasus Pharma (NSRX) Short-term Investments (2025)

Nasus Pharma (NSRX) reported Short-term Investments of $3.0 million for Q4 2025.

Nasus Pharma (NSRX) Short-term Investments (2025) Analysis & Trends

Nasus Pharma has reported Short-term Investments for 1 years, with the latest figure at $3.0 million in Q4 2025.

For the quarter ending Q4 2025, Short-term Investments changed N/A year-over-year to $3.0 million; the trailing twelve-month figure through Dec 2025 stood at $3.0 million (changed N/A YoY), and the FY2025 full-year result was $3.0 million, changed N/A from the prior year.
Short-term Investments for Q4 2025 stood at $3.0 million.
The five-year high for Short-term Investments was $3.0 million in Q4 2025, with the low at $3.0 million in Q4 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn
10	Nasus Pharma	24.83 Mn	20.55 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2025	3.05 Mn